ARTICLE | Finance

Aducanumab approval lifts shares of biotechs with Alzheimer’s programs

Biogen and Lilly together gain $36B in market cap

June 7, 2021 11:30 PM UTC

FDA’s willingness to approve Biogen’s aducanumab based on a surrogate endpoint rather than clinical benefit has created the perception that other biopharmas with Alzheimer’s programs may have a lower bar to attain for approval than previously thought, driving up stocks Monday and adding a total of $36 billion in market cap to Biogen and Lilly.

At a press briefing shortly after Monday’s approval, FDA officials indicated the move could set a precedent in neurodegenerative diseases for greater use of accelerated approval, and it hopes that the field will benefit from the pathway as oncology has...

BCIQ Company Profiles

Biogen Inc.

Eli Lilly and Co.

BCIQ Target Profiles

Beta amyloid